AzurRx BioPharma Inc. (NASDAQ:AZRX) and Intellia Therapeutics Inc. (NASDAQ:NTLA) compete against each other in the Biotechnology sector. We will compare them and contrast their analyst recommendations, profitability, risk, dividends, institutional ownership, earnings and valuation.

Valuation and Earnings

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AzurRx BioPharma Inc.	N/A	0.00	11.99M	-0.88	0.00
Intellia Therapeutics Inc.	30.43M	27.38	85.34M	-2.16	0.00

Table 1 shows gross revenue, earnings per share and valuation of the two companies.

Profitability

Table 2 provides us AzurRx BioPharma Inc. and Intellia Therapeutics Inc.’s return on assets, return on equity and net margins.

	Net Margins	Return on Equity	Return on Assets
AzurRx BioPharma Inc.	0.00%	-301.4%	-154.5%
Intellia Therapeutics Inc.	-280.45%	-30.6%	-25%

Liquidity

3.9 and 3.9 are the respective Current Ratio and a Quick Ratio of AzurRx BioPharma Inc. Its rival Intellia Therapeutics Inc.’s Current and Quick Ratios are 8 and 8 respectively. Intellia Therapeutics Inc. has a better chance of clearing its pay short and long-term debts than AzurRx BioPharma Inc.

Insider & Institutional Ownership

Roughly 16.3% of AzurRx BioPharma Inc. shares are held by institutional investors while 74.6% of Intellia Therapeutics Inc. are owned by institutional investors. Insiders held roughly 5.4% of AzurRx BioPharma Inc.’s shares. On the other hand, insiders held about 24.01% of Intellia Therapeutics Inc.’s shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
AzurRx BioPharma Inc.	-1.44%	-2.97%	3.54%	-18.65%	-21.46%	69.42%
Intellia Therapeutics Inc.	15.53%	17.33%	-2.93%	-44.98%	-34.45%	21.54%

For the past year AzurRx BioPharma Inc.’s stock price has bigger growth than Intellia Therapeutics Inc.

Summary

On 5 of the 9 factors Intellia Therapeutics Inc. beats AzurRx BioPharma Inc.

AzurRx BioPharma, Inc., a clinical development stage biopharmaceutical company, engages in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders. Its product pipeline consists of two therapeutic proteins under development, including MS1819, an autologous yeast recombinant lipase, which is in Phase IIa trial for the treatment of exocrine pancreatic insufficiency associated with chronic pancreatitis and cystic fibrosis; and AZX1101, a recombinant b-lactamase combination of bacterial origin for the prevention of hospital-acquired infections, as well as antibiotic-associated diarrhea. The company was incorporated in 2014 and is headquartered in Brooklyn, New York.

Intellia Therapeutics Inc., a gene editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, hepatitis B virus, and inborn errors of metabolism programs. Its ex vivo pipeline includes proprietary and partnered programs focuses on chimeric antigen receptor T cells and hematopoietic stem cells. Intellia Therapeutics Inc. has collaboration agreement with Novartis Institutes for BioMedical Research, Inc.; Regeneron Pharmaceuticals, Inc.; and Caribou Biosciences, Inc. The company was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics Inc. in July 2014. Intellia Therapeutics Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.